Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Free Report) – Analysts at Alliance Global Partners lowered their FY2024 EPS estimates for shares of Curaleaf in a report released on Wednesday, October 30th. Alliance Global Partners analyst A. Grey now expects that the company will earn ($0.27) per share for the year, down from their previous estimate of ($0.26). The consensus estimate for Curaleaf’s current full-year earnings is ($0.24) per share. Alliance Global Partners also issued estimates for Curaleaf’s Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.21) EPS.
Other analysts have also issued reports about the stock. Cormark raised shares of Curaleaf from a “hold” rating to a “moderate buy” rating in a research report on Monday, August 12th. Needham & Company LLC reissued a “buy” rating and issued a $6.25 price objective on shares of Curaleaf in a research report on Thursday, August 8th.
Curaleaf Stock Down 2.0 %
Curaleaf stock opened at $2.89 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.09 and a quick ratio of 0.50. Curaleaf has a 1-year low of $2.56 and a 1-year high of $6.40. The company’s 50-day moving average is $3.02 and its 200 day moving average is $3.91.
Curaleaf (OTCMKTS:CURLF – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Curaleaf had a negative return on equity of 14.75% and a negative net margin of 18.59%. The firm had revenue of $342.29 million during the quarter, compared to analysts’ expectations of $344.57 million.
Curaleaf Company Profile
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
- Five stocks we like better than Curaleaf
- Using the MarketBeat Dividend Yield Calculator
- Starbucks Stock Primed for Growth Under New CEO Niccol’s Vision
- What is the FTSE 100 index?
- 3 Large-Cap Stocks Primed for a Year-End Melt-Up Rally
- Investing In Preferred Stock vs. Common Stock
- Roblox Stock Set for More Gains After Strong Earnings Report
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.